SCHEMBL4845353

SCHEMBL4845353

COCCN/C(=N\C#N)Nc1cc(NC(=O)c2sccc2NCc2ccnc3ccccc23)ccc1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.53
KIT P10721 6/20 0.53
CYP3A4 P08684 3/20 0.53
LCK P06239 2/20 0.53
RAF1 P04049 1/20 0.53
RET P07949 1/20 0.53
MAP3K20 Q9NYL2 1/20 0.53
RIPK3 Q9Y572 1/20 0.53
FLT1 P17948 4/20 0.39
MAPK8 P45983 2/20 0.37
MAPK10 P53779 2/20 0.37
MAPK9 P45984 1/20 0.37
BRAF P15056 4/20 0.37
ALDH1A1 P00352 2/20 0.34
CYP2C19 P33261 2/20 0.34
CYP1A2 P05177 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
LYN P07948 1/20 0.34
HCK P08631 1/20 0.34
SRC P12931 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4845360 1.00 KDR (0.53) KDRKITCYP3A4LCKRAF1
SCHEMBL4845684 0.92 KDR (0.60) KDRKITCYP3A4LCKRAF1
SCHEMBL4845678 0.92 KDR (0.60) KDRKITCYP3A4LCKRAF1
SCHEMBL4845452 0.92 KDR (0.54) KDRKITCYP3A4LCKRAF1
SCHEMBL4845456 0.92 KDR (0.54) KDRKITCYP3A4LCKRAF1
SCHEMBL4848368 0.91 KDR (0.56) KDRKITCYP3A4LCKRAF1
SCHEMBL4848373 0.91 KDR (0.56) KDRKITCYP3A4LCKRAF1
SCHEMBL4853668 0.88 KDR (0.52) KDRKITCYP3A4LCKRAF1
SCHEMBL4853673 0.88 KDR (0.52) KDRKITCYP3A4LCKRAF1
SCHEMBL4852051 0.86 KDR (0.55) KDRKITCYP3A4LCKRAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060074082-A1 (Arylamidoaryl)cyanoguanidine compounds OSI PHARMACEUTICALS, INC. 2006-04-06 US claimed
US-7439256-B2 (Arylamidoaryl) cyanoguanidine compounds OSI PHARMACEUTICALS, INC. 2008-10-21 US disclosed
US-7439256-B2 (Arylamidoaryl) cyanoguanidine compounds OSI PHARMACEUTICALS, INC. 2008-10-21 US disclosed
US-7439256-B2 (Arylamidoaryl) cyanoguanidine compounds OSI PHARMACEUTICALS, INC. 2008-10-21 US disclosed
US-20060074082-A1 (Arylamidoaryl)cyanoguanidine compounds OSI PHARMACEUTICALS, INC. 2006-04-06 US disclosed
WO-2006034110-A1 (ARYLAMIDOARYL) CYANOGUANIDINE COMPOUNDS AS INHIBITORS OF C-KIT PROTO-ONCOGENE OSI PHARMACEUTICALS, INC. (US) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074082-A1 (Arylamidoaryl)cyanoguanidine compounds NQO2, NRAS, Q6ZSR9 KDR 1751/4885KIT 1210/4885CYP3A4 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.